Podcasts about plant medicine podcast

This episode of the Plant Medicine Podcast welcomes Dr. Angela Carter (they/them) to discuss the intersection of the LGBTQIA2S+ community and psychedelics. Dr. Carter is a queer, transgender, and genderqueer naturopathic primary care physician who also works as a midwife, sexual assault examiner, and health equity advocate in Portland, Oregon. They also serve as both the vice-chair and the equity in training subcommittees co-chair of the Oregon Psilocybin Advisory Board. In addition to these positions, Dr. Carter serves as the chair of the Transgender Health Program Community Advisory Board at Oregon Health & Science University. They also volunteer with many organizations including the Fireside Project, Black Rock City Emergency Services, and Queerdome.  Dr. Carter begins this conversation by sharing exciting new research currently being conducted which involves LGBTQIA2S+ individuals and psychedelic therapies. While this particular area of research remains small, it is growing and the fruits of these studies will be an important step for better understanding how these new therapies can serve gender and sexuality minorities, and help facilitators understand the unique concerns of people in the LGBTQIA2S+ community. Dr. Carter illustrates these types of concerns by discussing the prevalence of gender binaries within psychedelic spaces. They describe how in a clinical setting it is prevalent to have both a male and a female facilitator, but this leaves no room for gender-nonconforming people to guide experiences—something which could be preferable if the patient themselves shares this identity.  Dr. Carter also discusses this gender binary in traditional contexts. It is common for ayahuasca ceremonies to provide separate spaces for men and women, again leaving no space for gender-nonconforming people. This reification of the gender binary and the often patriarchal organization of the ayahuasca ceremony can have serious impacts on the set and setting, especially for people in the LGBTQIA2S+ community. Dr. Carter emphasizes the importance of making space for folks in the community so that they are able to receive therapy, attend ceremonies, and participate in integration with others who share similar identities. This shared identity, they emphasize, ensures that LGBTQIA2S+ people don't feel out of place in contexts that ought to be healing. Dr. Carter closes by discussing how members of the LGBTQIA2S+ community experience disproportionate rates of mental illness, further illustrating the crucial importance of equity in accessing psychedelic medicine.    In this episode: Problems of representation and access for LGBTQIA2S+ individuals in the psychedelic space Current research being done on the intersection between psychedelic therapies and unique issues faced by gender and sexuality minorities Preparations to take before guiding a psychedelic experience for LGBTQIA2S+ people, particularly if you do not come from the community How plant medicines could have unique benefits for the LGBTQIA2S+ community Issues of poverty faced by marginalized peoples and how to support equity of access to emerging psychedelic therapies   Quotes: “For some people that idea of melding, of becoming one and losing all of those unique pieces of themselves, doesn't fit their paradigm of a spiritual connecting experience.” [10:47]  “It's precious, that centering of our community—to be able to sit with people who just understand.” [19:42]  “Psychedelics offer the opportunity for connection of the self to something greater, something outside, a bigger community, spirituality, and really do a huge amount to heal peoples' relationships with substances.” [25:20]  “Marginalized communities have been really impacted, largely, by the war on drugs, which has put millions of people in jail for drug offenses and stolen their ability to make income, stolen their ability to connect with community and we really need to heal that.” [33:34]   Links: Chacruna Institute Queering Psychedelics 2019 Conference Queerdome on Facebook  Portland Psychedelic Society Psychedelic Medicine Association Porangui

In this episode of the Plant Medicine Podcast, Dr. Mark Braunstein returns to discuss potential concerns surrounding the use of ketamine, especially use which is not overseen by a knowledgeable medical professional. Dr. Braunstein is a whole-health psychiatrist with 22 years of clinical experience. He is the medical director for multiple mental health and psychedelic psychotherapy clinics in Colorado, New Mexico, and Utah and he also runs in-patient and out-patient programs for addiction. Additionally, Dr. Braunstein is involved in multiple projects focused on expanding access, awareness, research, and safety in the field of psychedelics. To begin this conversation, Dr. Braunstein shares how his original exposure to ketamine wasn't in a medicinal context, but rather as a recreational drug of abuse. However, since then he has seen the transformative effects this substance can have on patients when used in a physician-directed context and for therapeutic purposes. Nonetheless, Dr. Braunstein stresses that this does not mean ketamine use does not come with certain risks. Ketamine can be addictive and even carries a risk of overdose, particularly when used recreationally in a context where the purity of the substance is unknown. Dr. Braunstein distinguishes recreational and therapeutic uses of ketamine, explaining that recreational doses are often lower and dosing is more frequent, whereas ketamine is used in high doses in a therapeutic context, with extended periods between sessions. Dr. Braunstein stresses both the responsibility of physicians and of patients to ensure ketamine is prescribed responsibly and used as directed. Despite the dangers posed by recreational ketamine use Dr. Braunstein describes in this conversation, it is still a medicine he believes can have significant positive impacts for patients. This requires, however, that it not be treated merely as yet another quick fix pill. Instead, Dr. Braunstein emphasizes that ketamine treatment ought to coincide with psychotherapeutic work. This combination, he says, will maximize the therapeutic potential of ketamine while also helping to ensure that the medicine is used responsibly, under the close direction of a medical professional.   In this episode: The addiction and overdose potential with recreational ketamine use How dosage can dramatically change the effects of ketamine Responsible prescribing practices for physicians working with ketamine The psychological and physiological harms of ketamine abuse How Dr. Braunstein talks to his patients about responsible use before prescribing ketamine The importance of combining psychedelic medicines with psychotherapeutic work   Quotes: “Part of why ketamine works is because it lights up your brain in all these different ways and when done occasionally, intentionally, it moves you. But if you're always doing that, it ends up having the reverse effect, causing damage.” [12:56] “This is a heavy-duty medication that, if you cross the line, can cause you to stop breathing and then die. So there is an actual, real danger to ketamine.” [16:25] “I think the organ that is most prone to damage from overuse of ketamine is the same organ we are touting it fixing: the mind.” [18:39] “When we think about these medications, we should think about combining them with therapy and not just taking these medications as medications… So that's why with ketamine I'm really recommending it with therapy.” [25:04]   Links: Reconscious Medical Psychedelic Medicine Association Porangui

We are so excited to share this powerful conversation with our friends and special guests, Tah and Kole Whitty. They host the Psychedelic Coach podcast and are co-creators of The Condor Approach, which is a psychedelic-informed certification for therapists, physicians, life coaches, and health experts. In this episode you'll hear their journeys that got them into the psychedelic space, how you can personally explore psychedelics, the importance of how we integrate, tuning into your intuition, and more!Tah and Kole Whitty are leading experts in the field of integration and psychedelics, known for their work in guiding individuals toward lasting transformation. Tah has over 30 years of nursing experience, particularly in emergency rooms all over New York City. Kole is a former Miss Utah Teen USA, international substance abuse educator turned psychedelic enthusiast. Together, they co-host The Psychedelic Coach Podcast and have co-created The Condor Coach Certification, a psychedelic-informed training that provides practitioners with a unique perspective on the integration process. The Whittys helped thousands improve their health in the fitness space before shifting full-time into transformational work. They have led hundreds of events worldwide and are now certifying coaches of all kinds to be psychedelic-informed to meet the growing demand need for support. With tens of thousands flocking to places like Costa Rica and Peru, many are returning home with little to know idea what to do next. Between their personal journeys, expertise, and mission to certify 10,000 coaches by 2027, they predetermined to set a new standard for coaching.This Austin power couple has been seen in documentaries like Psychedelics Revealed, a Hays Film, and featured at events like Paleo fx and Aubrey Marcus' Fit For Service, and countless top podcasts like Mindset Mentor with Rob Dial, The Mike Dillard Podcast, The Plant Medicine Podcast, Lifestylist Podcast - Luke Storey and countless others.Integration is not optional, but how you integrate is.SHOW NOTES:0:55 Welcome to the show!3:06 Pop Quiz Question of the Day6:16 Today's topic and guests7:00 Renee's retreat in Costa Rica11:16 Tah & Kole's bio12:50 Welcome them to the podcast!13:48 Kole's story17:54 Tah's story23:36 His first experience with Ceremony25:01 Tah's run with insomnia26:44 The beginning of their facilitation journey27:29 Working with Biohackers & Functional Med Practitioners30:37 ACE Scores vs Symptomology31:39 Threats to our “mental constructs”32:49 The spectrum of trauma & diminishing emotions35:54 Visualizing contraction/dissociation vs openness37:10 *Nootopia*39:14 The internalization of shame & guilt42:54 Psychedelics as an opportunity for curiosity44:34 How does someone get started?49:44 What you need to know about Psilocybin strains50:21 Importance of being “psychedelic-informed”5220 The Expansion Equation54:12 Exposing yourself to other narratives & Indigenous practices57:56 *Silverbiotics*59:36 Why you need to get over yourself1:02:03 Listening to your body's cues1:05:59 Why Lauren biohacks1:05:45 ‘Integration Is Not Optional'1:09:22 Renee's experience with intuition on retreat1:10:23 When your body says NO1:14:59 Bypassing micro-traumas1:18:22 Listening to our bugs & biome1:21:54 Educating psychedelic-informed coaches1:23:09 Where to learn more1:27:26 Their final piece of advice1:31:56 Thanks for tuning in with us!RESOURCES:tahkole.comCondorApproach.comIG: thecondorapproachCondor Coaching CertificationThe Psychedelic Coach PodcastKole's IG: @mystikoleTah's IG: @psychedelicnurseBook: The Mind Body CodeThe Condor Approach 7-Day Integration GuideSapiensoup.comNootopia.com - discount code: BIOHACKERBABES10Silverbiotics.com - discount code: BIOHACKERBABESSupport this podcast at — https://redcircle.com/biohacker-babes-podcast/donationsAdvertising Inquiries: https://redcircle.com/brands

In this episode of the Plant Medicine Podcast, Adam Aronovich returns to discuss the phenomenon of psychedelic narcissism. Adam is a doctoral candidate at the Universitat Rovira i Virgili in Spain, focusing on Medical Anthropology and Cultural Psychiatry. He is an active member of the Medical Anthropology Research Center (MARC) and part of the Ayahuasca Community Committee at the Chacruna Institute for Psychedelic Plant Medicines. In the last four years he has conducted extensive fieldwork in the Peruvian Amazon, where he has been doing qualitative research in collaboration with ICEERS, the Beckley Foundation, and, more recently, the Centre for Psychedelic Studies at Imperial College. Beyond his work conducting and coordinating research, Adam regularly facilitates workshops at the Temple of the Way of Light, a prestigious healing center in the Iquitos area. In this wide-ranging conversation, Adam unpacks some of the darker sides of the modern psychedelic movement, discussing the psychosocial dynamics around psychedelic use which can lead to things such as ego inflation, conspiratorial thinking, and narcissism. Adam recalls his own experiences slipping into messianic fantasies during a period of initial enthusiasm around psychedelic experiences. He views issues of alienation and lack of social support as being instrumental in leading to these types of delusions following profound spiritual experiences. While it is difficult to reach people who've slipped into psychedelic narcissism, Adam suggests that communal support is the best safeguard against these dangers and the most effective strategy for grounding people who've lost touch with reality. Drawing on his academic expertise, Adam distinguishes traditional uses of plant medicines from the Western paradigm for approaching psychedelics. He stresses the relational and communal aspects of the spiritual traditions which use psychedelics ceremonially. The pro-social aspects of these wisdom traditions, he claims, help safeguard against the traps of psychedelic narcissism and ego inflation, as there are established mechanisms for keeping people grounded following intense spiritual experiences.  Adam closes the discussion with an insightful analysis of modern gurus and self-proclaimed shamans. Adam encourages people to beware of deeply held spiritual fantasies, where a master can appear as more than human. Instead, he emphasizes that even skillful and well-intentioned healers are themselves nothing more than human beings, so there will always be imperfection and messiness. This does not, however, mean that impactful work cannot happen—in fact, this insight helps protect against the idolization of charismatic psychedelic personalities, which can lead to harmful experiences.   In this episode: Defining psychedelic narcissism Clinical vs colloquial understandings of narcissism The intersections of the psychedelic movement and conspiracy theories The importance of social and communal support for avoiding ego inflation following psychedelic or spiritual experiences How psychedelic experiences can actually deepen ego attachments and accentuate narcissistic tendencies The importance of humor in combating spiritual narcissism   Quotes: “Many of the underlying ideologies upon which Western cultures were built, like hyper-individualism and so on, kind of predispose us and prime us for certain aspects of narcissism.” [5:36] “Ego inflation, spiritual narcissism, messianic episodes—all of these are things that are fairly common within both people who are in some sort of spiritual or psychedelic path.” [12:17] “In traditional societies for the most part really there isn't such a thing as a self-proclaimed shaman. A person doesn't wake up one morning and is like ‘oh, I'm the shaman'—that's a title or a role or a recognition given to that person by the community.” [38:03] “The best measure of whether somebody is genuine and helpful is not whatever credentials or titles he assigns to himself, but rather what other people feel. So, you know, you will know a tree by its fruits.” [45:08] “Having these experiences by themselves does not necessarily mean spiritual growth or psychological development or any enhanced benefit if we're not constantly, painfully, mindful of how we actually integrate and embody those things in daily life over very long periods of time.” [54:29]   Links: Adam on Instagram Temple of the Way of Light Psychedelic Medicine Association Porangui

Gerardo's book is a masterpiece: Brave, bold, timely, selfless, and truly an inspirational program of overcoming. “Taking Back My Mind” is a game-changer for anyone seeking to heal to become the best versions of themselves. In our spirited conversation we talk psychedelic medicines, integration practices: Wim Hof & Stoicism. And we aggressively confront the failed war on drugs and the carnage left in its wake.    Show Notes Gerardo Urias:   We discuss; -Gerardo's journey with psychedelic medicines [4:40] -How we treat ourselves is how we treat others [10:20] -Wim Hof & Psychedelics [13:40] -Inspired by Tim Ferriss's 80/20 rule [16:15] -How stoicism helps us integrate psychedelic healing [21:00] -Amor Fati: Love Your Fate! [23:45] -An invitation for 10X growth [36:20] -Flow is the answer [40:00] -Thoughts on the failed, unjust, racist War on Drugs [45:00] -60/70s vs our current psychedelic renaissance [59:20]     Useful Resources:    “Stealing Fire” by Steven Kotler/Jamie Wheal, Plant Medicine Podcast w/Dr. Lynn Marie Morski's  Psychedelic Medicine Association    Contact Gerardo Urias:   FB: @takingbackmymind IG: @gerardourias77 https://takingbackmymind.com/ “Taking Back My Mind” Please support a brave first time author and pick up a copy of Gerardo's game-changer book

Microdose Monday EP 3- Micro dosing to help with addiction  Tucker talks about the benefits of microdosing with Psilocybin, bufo, and Iboga 

In this episode of the Plant Medicine Podcast, Matt Johnson, PhD returns to discuss previous survey research he conducted regarding DMT entities. Dr. Johnson is the associate director at the Center for Psychedelic and Consciousness Research at Johns Hopkins University, where he also works as a professor of psychiatry and behavioral sciences. He has published widely in the field of psychedelic science and has guided over one hundred psychedelic experiences. In 2019 Dr. Johnson was the president of the psychopharmacology division of the American Psychological Association, and he currently serves as the president of the International Society for the Research on Psychedelics. In this conversation, Dr. Johnson shares findings from his 2020 publication of survey research which investigates peoples' experiences with DMT entities. To preface these findings, however, Dr. Johnson first lays the groundwork by explaining the limitations of scientific investigation into these kinds of psychic phenomena. He explains that science is unable to answer questions of whether or not DMT entities are ultimately real, or what the fundamental nature of these experiences is. It can, however, employ rigorous methods for analyzing reports of entity encounters in order to document common features of these experiences and the types of effects they can have on individuals. In the survey, around twenty five hundred respondents shared their experiences of encountering an entity during a DMT experience. From the data collected, Dr. Johnson shares some of the common features of these entities. The beings are typically perceived as benevolent though there was a wide variety of ways the entities were conceptualized, ranging from aliens and machine elves to spirits and angels. Often participants believed the entities revealed metaphysical realities and the presence of these beings was frequently accompanied by extrasensory phenomena such as telepathic communication. Due to the dramatic nature of these experiences, Dr. Johnson's research found some lasting impacts as reported by respondents, and he concludes by briefly discussing the effects of entity encounters on religious belief.    In this episode: What questions science can and can't answer, and the boundaries good scientific research has to take when investigating something such as DMT entities The findings of Dr. Johnson's survey research—some general trends regarding the qualities of entities described Effects of entity encounters on religious belief   Quotes: “My bet is that if people believe that there's some sort of reality to these disincarnated entities—that it's not just in their mind—there are certain people that can hold that experience in a positive way that might benefit them… and probably some of these over 2,000 folks, there's probably some people that—again, aside from whether we know it's true or not—believing in things that no one else can prove are there is probably a bad thing.” [12:38] “The machine elf thing, I mean, that was Terrence McKenna's trip. And he described it—and I think he was very honest that that was his experience—and I think people who've heard his experience, a good number of them have had machine elf experiences because they heard Terrence McKenna's experience.” [16:17] “Before the experience, 28% of these people identified as atheist, and then after the encounter that dropped to 10%.” [20:53]   Links: Center for Psychedelic & Consciousness Research at Johns Hopkins (contribute to survey research here) Dr. Johnson's DMT Entity Study: Survey of Entity Encounter Experiences Occasioned by Inhaled N,N-Dimethyltryptamine: Phenomenology, Interpretation, and Enduring Effects Psychedelic Medicine Association Porangui

In this episode of the Psychedelic Medicine Podcast (formerly the Plant Medicine Podcast), Rick Doblin joins to discuss the past, present, and future of MDMA-assisted therapy. Rick Doblin is the founder and executive director of the Multidisciplinary Association for Psychedelic Studies. He received his doctorate in public policy from Harvard and has also studied under the father of transpersonal psychology Stanislav Grof. Through MAPS, Rick aspires to develop legal contexts for beneficial uses of psychedelics and marijuana as prescription medicines, but also for self-development and personal growth in otherwise healthy individuals. Rick begins this wide-ranging conversation discussing the early days of MDMA. The compound was originally synthesized by famed chemist Alexander "Sasha" Shulgin and, unlike the classic serotonergic psychedelics, it was not scheduled under the Controlled Substances Act in the early 70s. It was during this period of legality that therapeutic uses of MDMA were first developed and it was only later that the drug became repurposed as a recreational substance to be used in social settings, which consequently led to its emergency scheduling by the DEA. Rick recalls his own initial experiences with the empathogenic compound, stating that he was initially skeptical of its value, prior to gaining first-hand experience. Following this experience, however, he became convinced of its therapeutic potential and he shares some of his own early experiences of using MDMA to help people heal, including a very touching tale of his own grandmother's struggle with depression. From here, Rick discusses the founding of MAPS and his decision to pursue education in policy in order to better understand strategies for furthering MDMA-therapy even while living under prohibition. Since that time, MAPS has gone on to do incredibly impactful work in developing studies researching the safety and efficacy of MDMA-assisted therapy, specifically for post-traumatic stress disorder. Rick shares the progression of these studies, highlighting the results from the most recent phase three investigations which are the last step prior to FDA approval for the therapeutic protocol. These studies show high statistical significance and an amazing effect size resulting from MDMA-assisted therapy, with results being mirrored at all research locations and showing durability over time.  Because of this amazing progress, Rick believes we are at the final stretch prior to full FDA approval for MDMA use in a therapeutic context for PTSD, and subsequent rescheduling of the substance by the DEA, which he believes will take place in mid to late 2023. This development will have broad global impacts, spurring other countries to promptly follow suit. Rick closes out this discussion by emphasizing the need for mass mental health in our day and age, and sharing MAPS' lofty goals of training thousands of therapists to hopefully bring psychedelic therapy to millions of patients in the coming decades.    In this episode: Rick Doblin's personal journey The history of the MDMA's synthesis and legality Rick's first experiences with MDMA and early experiments with MDMA therapy MAPS' “two-pronged” strategy for mass mental health Early efforts to get an MDMA therapy protocol approved by the FDA following prohibition The politics of concerns about MDMA neurotoxicity and how this impacted MAPS' early approach The results of the first phase three studies of MDMA for PTSD How FDA approval of MDMA will lead to an international cascade of approval and rescheduling Rick's predictions for psychedelic medicine in the years to come    Quotes: “What a lot of people don't know is that MDMA was a therapy drug before it was a party drug. And it was the party drug nature of it that really got it criminalized.” [7:38] “Seeing what it was like when it was legal and experiencing that, and experiencing situations where people would take it, the kind of experiences and healings, and learnings that people would have, was amazing.” [19:12] “What we need is, I believe, legal access to medicinal MDMA, covered by insurance, by trained professionals, and psychedelic clinics. And we also need a whole different kind of drug policy for non-medical use that involves honest drug education, access to pure substances, harm reduction, peer support, and also treatment on demand.” [21:08] “The irony here is that the first legal move against MDMA was illegal. The DEA did not have the authority to emergency schedule drugs.” [23:43] “FDA is legally bound to approve MDMA for PTSD if these [phase 3] studies generate statistically significant evidence of efficacy, and there are no new safety problems.” [40:27] “We think by the third quarter of 2023 we will have FDA approval assuming the second phase 3 study goes well. And then by the fourth quarter, the DEA has to reschedule [MDMA].” [51:18] “What's even greater is the 12-month follow-up data was 67% no longer had PTSD. So people kept getting better—not only was it durable, but they kept getting better.” [55:00] “The thing to emphasize here is that MDMA is not the treatment. The treatment is therapy. The MDMA makes the therapy more effective and there can be different kinds of therapy that are used with it.” [1:01:38]   Links: MAPS website Rick Doblin on Twitter Trip of Compassion Documentary The Way of the Psychonaut Books by Stanislav Grof Upcoming MAPS Psychedelic Science Conference 2023 Becoming an MDMA-Assisted Therapist with Shannon Carlin, MA, LMFT Psychedelic Medicine Association Porangui

In this episode of the Plant Medicine Podcast, Dr. Josh Woolley joins to discuss the differences between psilocin and psilocybin, and to share upcoming clinical research which will further clarify the safety profiles, subjective effects, and clinical uses of these psychedelic substances.  Dr. Woolley is an Associate Professor in Residence in the Department of Psychiatry and Behavioral Sciences at the University of California, San Francisco (UCSF) as well as a staff psychiatrist in Mental Health at the San Francisco Veterans Affairs Medical Center (SFVAMC). He is Board Certified in Psychiatry by the American Board of Psychiatry and Neurology. He is the Director of the Bonding and Attunement in Neuropsychiatric Disorders (BAND) lab at UCSF that focuses on understanding and treating social deficits in neuropsychiatric disorders including schizophrenia, substance use disorders, and mood disorders. He is also the Director of the Translational Psychedelic Research (TrPR) Program at UCSF, which brings together scientists and care providers across disciplines to understand how psilocybin, LSD, ketamine, MDMA, and related compounds impact the brain and other organ systems. In this conversation, Dr. Woolley begins by sharing a bit about TrPR and the upcoming research they will be conducting on psychedelics as a treatment for depression in individuals living with Parkinson's disease. Dr. Woolley then introduces the main topic of psilocin, psilocybin, and the differences between these two compounds. He explains that psilocybin is a prodrug for psilocin, meaning that the human body metabolizes psilocybin into psilocin, which is the compound responsible for the psychoactive effects produced by psilocybin-containing mushrooms.  Dr. Woolley's upcoming research will provide more concrete data on the differences between these two compounds, as TrPR will be testing both psilocybin and psilocin in healthy volunteers, giving each participant both substances on different occasions so that effects can be studied both across the sample pool and within individuals. Dr. Woolley hypothesizes that psilocin could have certain clinical advantages over psilocybin: it could produce more consistent effects person-to-person at a given dose as individual differences in metabolism would be less relevant; it may more quickly induce a psychedelic experience, particularly when administering psilocin sublingually; and it is possible there may be fewer side effects related to the gastrointestinal tract. Dr. Woolley closes out the discussion by sharing other upcoming research to be conducted by TrPR. In addition to the study investigating psilocin and the research into psychedelics for Parkinson's disease, TrPR is also investigating the use of psychedelics to improve quality of life for individuals suffering from chronic pain and they will also be further investigating the interaction between psychedelics and bipolar disorder.    In this episode: The approach of the Translational Psychedelic Research (TrPR) Program and its upcoming research The pharmacological differences between psilocybin and psilocin and how the experience induced by the substances may differ In-subject study design and how it is used in Dr. Woolley's psilocin trials The mechanisms for tolerance with using psychedelic drugs Data on the contraindication of psychedelic use for individuals with bipolar disorder   Quotes: “For a long time, when you make [psilocin] synthetically—[...]—psilocin wasn't stable. So, even if you made psilocin synthetically you would then turn it into psilocybin so it would be stable and then people would take it and it would get turned back into psilocin.” [8:39] “You can't do sublingual psilocybin because it won't get broken down easily. But, sublingual psilocin doesn't need to be metabolized and it can go across your buccal membrane, skipping the gut. That theoretically could be useful because then you might skip the first pass metabolism, it doesn't have to go to the liver, and it might be faster that way and maybe again more consistent. And fewer side effects—maybe you won't get any GI side effects if it doesn't go to the GI tract.” [19:58] “We think that psychedelics—psilocybin in particular—might be able to change people's relationship to their [chronic] pain. It might be an analgesic too—it might make the pain go away, that would be great. But even if it doesn't do that, we think that it should allow people to basically find the pain less impairing.” [41:22]   Links: The Translational Psychedelic Research (TrPR) Program at UCSF Psychedelic Medicine Association Porangui

This episode of the Plant Medicine Podcast features a conversation with Dr. Carey Clark, discussing delta-8 THC. Dr. Clark is a registered nurse and an expert in cannabis care nursing. She holds a PhD from the California Institute of Integral Studies and is the immediate past president of the American Cannabis Nurses Association. She is also the editor and author of the first nursing textbook on medical cannabis Cannabis: A Handbook for Nurses and has over thirty publications in academic journals. Currently Dr. Clark serves as a professor at Pacific College of Health and Science where she also developed the first college-level, academic certificate in medical cannabis. In this conversation Dr. Clark introduces delta-8 THC, discussing its chemistry, pharmacology, and legal status. She begins by sharing that delta-8 is a minor cannabinoid which exists naturally in small quantities within cannabis and hemp. Delta-8 THC is chemically very similar to delta-9 THC—the primary cannabinoid within cannabis which is known for its mind-altering and medicinal properties—and in fact, delta-9 naturally degrades into delta-8 under certain conditions. Due to the structural similarities, delta-8 produces similar effects to delta-9, and may have similar medical applications. Dr. Clark mentions that delta-8 may be synthesized from CBD, allowing for this compound to be readily produced from legal components. However, the delta-8 which results from these synthesis methods contains traces of unknown compounds, perhaps as a result of the particular solvents used in the reaction, so Dr. Clark cautions that consuming these products could have certain risks, though the delta-8 cannabinoid itself is thought to have a similar safety profile to delta-9 THC. Instead. Dr. Clark emphasizes that whole plant medicines are likely the ideal for patients seeking to treat medical conditions with cannabis, but since delta-8 may be more readily available in certain areas due to its murky legal status it may be the best option for some individuals.  While scientific research into delta-8 is currently lacking, Dr. Clark shares the results from a few studies which use animal models and one study looking at the effects of delta-8 in the context of pediatric oncology. In addition to these published studies, Dr. Clark also shares anecdotal reports from patients, saying that these experiences are crucial, preferring to think of these reports as qualitative data which has yet to be systematically studied.   In this episode: What delta-8 THC is and how it is made Potential safety concerns with delta-8 products The current research on delta-8 The legal grey-area of delta-8 THC and states which have banned the cannabinoid Differences in the doses and effects of delta-8 and delta-9 THC   Quotes: “My hope as well is that people who are able to access whole-plant medicine can really use whole-plant medicine safely and effectively and they have access to safe, effective medicines. That would be my recommendation—if somebody had a choice—over choosing a really synthesized medicine at this point because of the safety issues.” [15:30] “[T]there's still very little research and most of the patient experience we're hearing is really anecdotal.” [24:52]   Links: Dr. Clark's faculty page at Pacific College of Health and Science Psychedelic Medicine Association Porangui

Lynn-Marie Morski, MD, JD is the president of the Psychedelic Medicine Association, host of the Plant Medicine Podcast, founder of Plant Medicine.org, and the medical director for Way of Leaf.com. Lynn-Marie is a Mayo Clinic-trained physician in family medicine and sports medicine, as well as an attorney and former adjunct law professor. She started the Plant Medicine Podcast to bring scientific researchers, practitioners, and those who have been personally affected by the healing powers of these plants together to help educate the public on what is possible and help further research and decriminalization of these substances. She later founded The Psychedelic Medicine Association; a society of physicians, therapists, and health care professionals looking to advance their education on the therapeutic uses of psychedelic medicines.The Psychedelic Medicine Association (PMA) is a public benefit corporation of healthcare providers aimed at bridging the gap between the advances taking place in the psychedelic research world and medical practitioners.In this episode:Factors that influence which psychedelic medicine is best suited for the patientLynn-marie's therapeutic realisation Fundamentals of Psychedelic MedicineCommon myths or confusions in psychedelic medicineCurrent accessibility Western and indigenous perspectives of illness and wellness4 big hurdles preventing doctors prescribing psychedelicsHow to approach stigma within the health-care communityHarm reductionLinks:Psychedelic Medicine AssociationPlant Medicine Podcast (Spotify)PlantMedicine.orgSupport the podcast:Support the podcast (Patreon)Support Mind Medicine Australia's mission:Mind Medicine AustraliaDonate to Mind Medicine AustraliaJoin a local chapterSupport this show http://supporter.acast.com/mind-medicine-australia. See acast.com/privacy for privacy and opt-out information.

This episode of the Plant Medicine Podcast features a conversation with Kyle Buller on psychedelics and breathwork. Kyle is co-founder and host of the Psychedelics Today podcast and he has studied breathwork since October 2010 with Lenny and Elizabeth Gibson of Dreamshadow Transpersonal Breathwork. Kyle earned his BA in transpersonal psychology from Burlington College where he focused on the healthing potential of non-ordinary states of consciousness, exploring topics such as shamanism, reiki, plant medicine, and holotropic breathwork. He has also earned an MS in clinical mental health counseling with emphasis in somatic psychology and has since worked with at-risk teens in crisis and individuals experiencing an early episode of psychosis. Kyle opens this discussion by providing a basic definition of breathwork and sharing his own journey with this modality. He discusses how breathwork can refer to a wide variety of practices, but what unites these disparate techniques is utilizing the breath to induce specific physiological states and experiences. The holotropic style of breathwork has roots in transpersonal psychology and the work of Stanislav Grof and it is this modality which is often compared to psychedelic experiences. Kyle discusses how holotropic breathwork can be an incredibly powerful practice for trauma-healing and inducing visceral experiences—similar to the classical psychedelics. He recounts his own experiences with this practice, describing how he was able to relive the experience of being born in the state conditioned by the method of breathing. Due to the synergy with the psychedelic experience, Kyle mentions that there is a lot of potential for breathwork to help individuals integrate or prepare for psychedelic experiences, as well as being a powerful tool for clinicians involved in psychedelic-psychotherapy to better understand the non-ordinary states of consciousness their patients will be experiencing.  Because of the wide variety of breathwork techniques, Kyle discusses the possibilities of tailoring practices to the specific experiences of a client. Everyone has a unique “window of tolerance” depending on their background and constitution, and some people will benefit more from techniques which downregulate the nervous system and allow for peace and relaxation, while others may find more value in techniques which are highly stimulating and provide deeper, emotionally complex experiences that allow for self-exploration.   In this episode: What breathwork is an how it relates to psychedelics The origins of holotropic breathwork and Stanislav Grof's transpersonal framework Breathwork vs meditation How to use breathwork to integrate and prepare for psychedelic experiences The effects of different types of breathing on the nervous system   Quotes: “[Breathwork] offered a really great tool for training, for understanding how to sit with people in non-ordinary states of consciousness.”  [8:49] “Some breathing techniques, like these more deeply cathartic techniques, they're bringing up a lot of emotional memory and people are starting to work through a lot of somatic sensations, they are working through trauma.” [13:38] “We really need to look at somebody's whole picture, where they're at, how they could potentially benefit, look at their nervous system, attune to that, and really think about what they could tolerate, what's going on in somebody's psyche.” [30:29] “The breath is this flexible tool, it's a vehicle—we can help to regulate our nervous system with it and explore it.” [39:38]   Links: Psychedelics Today Psychedelics Today Education Center SettingSun Wellness Dreamshadow Transpersonal Breathwork Psychedelic Medicine Association Porangui

In this episode of the Plant Medicine Podcast, Matt Johnson, PhD returns for the final installment to discuss his recent paper “Consciousness, Religion, and Gurus: Pitfalls of Psychedelic Medicine.” Dr. Johnson is the associate director at the Center for Psychedelic and Consciousness Research at Johns Hopkins University, where he also works as a professor of psychiatry and behavioral sciences. He has published widely in the field of psychedelic science and has guided over one hundred psychedelic experiences. In 2019 Dr. Johnson was the president of the psychopharmacology division of the American Psychological Association, and he currently serves as the president of the International Society for the Research on Psychedelics. In his paper, Dr. Johnson explores some concerns around certain norms which have developed in psychedelic therapy, and how these could have potential negative effects. Dr. Johnson raises two main concerns in this conversation. The first is how therapists, guides, and scientific researchers could advance various spiritual or religious beliefs within the therapeutic context or offer metaphysical interpretations of psychedelic experiences beyond what the client suggests.  The second concern involves how psychedelic medicine is presented, both on a cultural level and even materially within therapeutic settings. For example, Dr. Johnson suggests that it is inappropriate to have statues of the Buddha displayed in clinical settings, unless this is something requested by the client. He suggests that if psychedelic therapy embraces a certain “New Age” aesthetic wholesale, it could dissuade people who don't identify with the subculture from taking advantage of these therapies, especially as these medicines become more widely accessible.  Additionally, Dr. Johnson points out that not all patients would have the same associations with the Buddha statue in the example, and that the inclusion of any particular religious iconography should be something chosen proactively by the client, rather than assumed by the therapist. Dr. Johnson concludes this conversation by again stressing a client-centered approach to psychedelic therapy, suggesting that this approach is best suited to circumvent these concerning pitfalls.   In this episode: The issue with psychedelic therapists or guides bringing their own metaphysical beliefs into the psychedelic experience or its interpretation How the current culture around psychedelic medicine subtly presents these therapies as being for specific kinds of people How a client-centered approach from humanistic psychology can present an effective framework for psychedelic-assisted psychotherapy   Quotes: “I think it's critical that therapists—and scientists at this research phase we're at now—be client-centered in terms of the therapeutic approach. In other words, not making any assumptions for the participants, for the patients, about what the interpretation of these experiences should be.” [4:36] “You're there to support them, you're there to let them lead. If there's any metaphysical meaning to be made, they are in the driver's seat. You're there to create a safe container, to care for their wellbeing, and to allow them to have their experience.” [11:08] “It's not that you're denying any of this stuff—it very well may be that any of these people's framework is ground truth—it's just not your role to say and we don't need to.” [15:06]   Links: Center for Psychedelic & Consciousness Research at Johns Hopkins (contribute to survey research here) Dr. Johnson's Paper: Consciousness, Religion, and Gurus: Pitfalls of Psychedelic Medicine Psychedelic Medicine Association Porangui

In this episode of the Plant Medicine Podcast, Matt Johnson, PhD returns to discuss previous survey research he conducted regarding DMT entities. Dr. Johnson is the associate director at the Center for Psychedelic and Consciousness Research at Johns Hopkins University, where he also works as a professor of psychiatry and behavioral sciences. He has published widely in the field of psychedelic science and has guided over one hundred psychedelic experiences. In 2019 Dr. Johnson was the president of the psychopharmacology division of the American Psychological Association, and he currently serves as the president of the International Society for the Research on Psychedelics. In this conversation, Dr. Johnson shares findings from his 2020 publication of survey research which investigates peoples' experiences with DMT entities. To preface these findings, however, Dr. Johnson first lays the groundwork by explaining the limitations of scientific investigation into these kinds of psychic phenomena. He explains that science is unable to answer questions of whether or not DMT entities are ultimately real, or what the fundamental nature of these experiences is. It can, however, employ rigorous methods for analyzing reports of entity encounters in order to document common features of these experiences and the types of effects they can have on individuals. In the survey, around twenty five hundred respondents shared their experiences of encountering an entity during a DMT experience. From the data collected, Dr. Johnson shares some of the common features of these entities. The beings are typically perceived as benevolent though there was a wide variety of ways the entities were conceptualized, ranging from aliens and machine elves to spirits and angels. Often participants believed the entities revealed metaphysical realities and the presence of these beings was frequently accompanied by extrasensory phenomena such as telepathic communication. Due to the dramatic nature of these experiences, Dr. Johnson's research found some lasting impacts as reported by respondents, and he concludes by briefly discussing the effects of entity encounters on religious belief.    In this episode: What questions science can and can't answer, and the boundaries good scientific research has to take when investigating something such as DMT entities The findings of Dr. Johnson's survey research—some general trends regarding the qualities of entities described Effects of entity encounters on religious belief   Quotes: “My bet is that if people believe that there's some sort of reality to these disincarnated entities—that it's not just in their mind—there are certain people that can hold that experience in a positive way that might benefit them… and probably some of these over 2,000 folks, there's probably some people that—again, aside from whether we know it's true or not—believing in things that no one else can prove are there is probably a bad thing.” [12:38] “The machine elf thing, I mean, that was Terrence McKenna's trip. And he described it—and I think he was very honest that that was his experience—and I think people who've heard his experience, a good number of them have had machine elf experiences because they heard Terrence McKenna's experience.” [16:17] “Before the experience, 28% of these people identified as atheist, and then after the encounter that dropped to 10%.” [20:53]   Links: Center for Psychedelic & Consciousness Research at Johns Hopkins (contribute to survey research here) Dr. Johnson's DMT Entity Study: Survey of Entity Encounter Experiences Occasioned by Inhaled N,N-Dimethyltryptamine: Phenomenology, Interpretation, and Enduring Effects Psychedelic Medicine Association Porangui

In this episode of the Plant Medicine Podcast, Matt Johnson, PhD joins to discuss the latest research of psilocybin as a treatment for depression. Dr. Johnson is the associate director at the Center for Psychedelic and Consciousness Research at Johns Hopkins University, where he also works as a professor of psychiatry and behavioral sciences. He has published widely in the field of psychedelic science and has guided over one hundred psychedelic experiences. In 2019 Dr. Johnson was the president of the psychopharmacology division of the American Psychological Association, and he currently serves as the president of the International Society for the Research on Psychedelics. In this conversation, Dr. Johnson shares findings from his recent study in psilocybin treatment for depression and summarizes other major studies investigating this psychedelic's clinical applications. First, however, he discusses ongoing survey research he is conducting at the Center for Psychedelic and Consciousness Studies. The Psychedelic Change Survey for Anxiety, Depression, or PTSD is seeking volunteers who have intentionally used psychedelics (ayahuasca, mushrooms, LSD) or MDMA to treat these mental health conditions to collect data on the efficacy of these interventions. Dr. Johnson and his team are interested in collecting a variety of responses, so you are encouraged to participate to share your experiences with these substances and whether they provided beneficial results, led to negative outcomes, or anything in between. Dr. Johnson also spends some time discussing study design, as psilocybin research has begun to move into more sophisticated forms of clinical research. He describes the function of a randomized clinical trial such as his own study, and details the double-blind double-dummy setup of the recent psilocybin study at NYU. In his study, Dr. Johnson's participants were randomly selected for the immediate treatment group or the delayed treatment group, which served as a control. All participants were provided with two sessions of psilocybin assisted psychotherapy, and the data showed that there were large reductions in depression following treatment and these results remained statistically significant at follow ups. In the NYU study, Dr. Johnson describes that participants were given either a genuine psilocybin treatment followed by a placebo antidepressant to take regularly, or they were given a placebo in place of psilocybin followed by an approved antidepressant. This large study is particularly interesting as it directly compares psilocybin treatment for depression with traditional pharmaceuticals used to treat this condition. Here again, Dr. Johnson reports that the psilocybin treatment showed extremely promising results.    In this episode: Conditions for participating in Dr. Johnson's current survey research   How Dr. Johnson designs his studies and chooses how he analyzes the data collected The results of the first randomized study examining the use of psilocybin for depression How the preparation process for psilocybin-assisted therapy may be clinically useful as a standalone treatment   Quotes: “We and the group at NYU published larger studies with a high dose of psilocybin and found these very large reductions in both depression and anxiety in cancer patients, so that sorta paved the way for, hey if this works in cancer patients let's look more broadly.” [19:42] “I kind of view psychedelic therapy as sort of having everything we know about general psychotherapeutic processes under a magnifying glass.” [23:12] “I think it's fallen out of fashion, but if we just had people laying on couches all day with therapists they've developed a relationship with—if that was more of a thing, even without psychedelics or placebo psychedelics, that has real benefit.” [28:30]   Links: Center for Psychedelic & Consciousness Research at Johns Hopkins (contribute to survey research here) Dr. Johnson's Recent Study: Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial NYU Psilocybin Study: Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Psychedelic Medicine Association Porangui

In this episode of the Plant Medicine Podcast, Ifetayo Harvey & Mary Sanders, LCSW join to discuss people of color and psychedelics. Ifetayo is a writer, advocate and speaker who founded the People of Color Psychedelic Collective. She has also previously worked with both MAPS and the Drug Policy Alliance. Mary Sanders is a licensed clinical social worker whose work focuses on addressing trauma in communities of color and marginalized populations. She is a founding board member at the People of Color Psychedelic Collective and is a trained psychedelic-assisted psychotherapist from both CIIS and MAPS. Mary is also certified in trauma-focused cognitive behavioral therapy and is currently enrolled at the somatic experiencing trauma institute. This conversation with Ifetayo and Mary touches on many of the important topics in the intersection of the unique experiences of people of color and the use of psychedelic medicines. One immediate concern which has begun to be discussed more openly is that of POC representation in psychedelic spaces. Ifetayo and Mary both discuss this issue, mentioning how representation is especially crucial for something as vulnerable as psychedelic experiences, where facilitators are responsible for navigating a wide range of emotions which naturally arise in a ceremony or therapeutic setting. Having someone from one's own community in these spaces can facilitate healing, as there is less anxiety around needing to explain specific experiences or trauma. Despite these shortcomings of representation, psychedelic medicines have a lot of potential to provide healing for people of color in particular. Ifetayo and Mary discuss the experience of intergenerational trauma in communities of color and how psychedelics are able to shed light on this phenomenon. Ifetayo shares powerful experiences from the first People of Color Psychedelic Collective retreat before the pandemic and explains her own coming to consciousness of the brutality of slavery and Jim Crow and how dysfunctional behaviors which perpetrate intergenerational trauma originally developed as survival mechanisms for the black Americans who lived under these racist systems.  Mary also emphasizes that psychedelic healing for people of color needs to emphasize building community and creating strong interpersonal bonds. While the individual experiences provided by plant medicines are incredibly beneficial, the healing will be even more profound if it can be processed and integrated collectively, as people of color aren't only healing individual ailments, but collective traumas rooted in shared histories of oppression.     In this episode: The unique needs of POC not typically addressed in psychedelic ceremonies or integration circles The disconnect between the Western therapeutic paradigm of healing individuals vs the more communal approaches to healing in traditional black cultures and how to bridge this gap How People of Color Psychedelic Collective creates community and fosters opportunities for people of color involved with psychedelics The intersection of intergenerational trauma and psychedelic healing for people of color   Quotes: “Taking a medicine is a vulnerable state, where we have to be cautious: am I going to be minimized, are my visions going to be acknowledged and held with support and love and care?” [8:27] “Healing is relational and it's so important that we not only do the work in the therapy space but that we're out and about with our friends and our family and our community members, especially our community members that have similar life experiences and histories.” [19:24] “There's a very very strong stigma around addiction [and] overdose because our communities have been harmed in so many ways by policing and bad drug policies.” [25:22] “I think it's really about uplifting the people who are already doing the work and then also supporting the folks who want to do the work, like providing them with resources, education, mentorship. Things like that will help usher in a new generation of [POC] healers, practitioners, leaders.” [39:35]   Links: People of Color Psychedelic Collective Mary Sanders' EmPATH Center Drug Policy Alliance Dr. Carl Hart's Webpage National Harm Reduction Coalition Darren Springer's Webpage Fruiting Bodies Collective Psychedelic Medicine Association Porangui

In this episode of the Plant Medicine Podcast, Leor Roseman and Antwan Saca join to discuss their recently published paper: Relational Processes in Ayahuasca Groups of Palestinians and Israelis. Leor is a postdoc at the Centre for Psychedelic Research at Imperial College London, where he also received his PhD and masters under the supervision of Dr. Robin Carhart-Harris. Leor has diverse research interests related to psychedelics, ranging from the neuroscientific and therapeutic, to the phenomenological and psychosocial. Antwan is a graduate of the Arab American University of Jenin with a BA in public law and has extensive experience working for justice in Palestine. He has served as the director of programs at Holy Land Trust in Bethlehem and as a program coordinator for Holy Land Christian Ecumenical Foundation. Antwan has also worked as a research assistant for urbanization and geopolitical monitoring at the Applied Research Institute—Jerusalem. In this episode, Leor and Antwan discuss the details of the recent paper they co-authored which deals with impacts of ayahuasca on interpersonal peace building in the context of the Israel-Palestine conflict. The study consists of 31 in-depth interviews with Israelis and Palestinians who've participated in joint ayahuasca ceremonies and looks to investigate the impact of this psychedelic experience along three relational themes: unity-based connection, recognition and difference-based connection, and conflict-related revelations. Through open-ended interviews, Leor and Antwan were able to collect qualitative data from participants which allowed research conclusions to arise organically.  In the interviews, participants disclosed experiences of profound political revelations, connection with the land, and empathy for the other. Leor and Antwan stress that the initial motivations of the participants typically had little to do with notions of political peace-building and instead they were most often participating in these psychedelic ceremonies for reasons related to personal growth, so these outcomes arose naturally as a result of the intense interpersonal connections spurred by the psychedelic experience.  Though these ayahuasca ceremonies had significant positive impacts for both the Israelis and the Palestinian participants, Antwan notes the disparity of access to psychedelic healing for Palestinians and emphasizes that the “love for the other” the Palestinian participants experienced through the ayahuasca ceremonies is complicated due to the pervasive political supression and percarity experienced by Palestinians in their day-to-day lives. The study, however, demonstrates that profound experiences of connection through the use of psychedelic medicines are possible even in the context of a deep and traumatic geopolitical conflict. This opens the door for further study of the potential of psychedelics to facilitate conflict resolution and peace-building.   In this episode: How Leor and Antwan developed the idea for this study based on their personal backgrounds Different themes which came up in interviews with the Israelis and Palestinians in the study The moving story of a former Israeli military officer and how he experienced the pain of the Palestinian people during an ayahuasca ceremony How music and prayer in the ceremonies helped to encourage empathy and cultural connection among participants   Quotes: “It's not questionnaires, it's not about measuring things, it's about listening to stories and making meaning out of them.” [13:24] “Because the rituals were participatory and music and prayers were shared, a lot of times these opened up for people the strong connection to the other culture or the other people and that was very meaningful for many people.” [21:34] “A lot of us Palestinians end up in the interviews telling you ‘this is all amazing' and yet there is the reality, yet we live under this kind of suppression.” [29:11] “Not all people that came to the ceremonies came from the peace camp or from left-leaning camps. They come for psycho-spiritual growth, or even for physical illnesses… And they go there regardless of their politics.” [31:37]   Links: Full Article: Relational Processes in Ayahuasca Groups of Palestinians and Israelis Psychedelic Medicine Association Porangui

This episode of the Plant Medicine Podcast welcomes Dr. Sam Gandy to discuss the symbiotic relationship between psychedelic experiences and connection with nature. Dr. Gandy holds a PhD in ecological science from the University of Aberdeen and has conducted field research across the globe. He currently works as a research assistant at the Synthesis Institute and as a senior science writer at Wavepaths. He is also a collaborator with the Centre for Psychedelic Research at Imperial College London and was previously a scientific assistant to the director of the Beckley Foundation.  In this conversation, Dr. Gandy shares insights from his research into psychedelics and nature relatedness with special emphasis on his 2020 publication “The Potential Synergistic Effects between Psychedelic Administration and Nature Contact for the Improvement of Mental Health” (linked below). Dr. Gandy discusses the numerous overlaps between the experience of nature relatedness—the personal sense of being connected with the natural world—and the experiences induced by psychedelic substances. These overlaps cover a range of domains and all work to promote wellbeing. For example, Dr. Gandy reports that neuroticism decreases both as a result of positive psychedelic experiences and from spending quality time in nature. As high neuroticism can correlate with mental illnesses such as depression and anxiety, interventions that can impact this trait have significant therapeutic potential.  In addition to specific overlaps between the psychedelic experience and nature relatedness, Dr. Gandy also discusses how psychedelics and psilocybin in particular seem to increase a sense of nature relatedness. Considering these overlapping benefits and the symbiotic relationship between psychedelics and nature relatedness, Dr. Gandy provides some speculations for how nature can be more intentionally integrated into psychedelic therapies and ceremonies to maximize the therapeutic benefits of both. He mentions that even something as small as decorating a clinical setting with artwork depicting nature can have positive impacts for patients undergoing psychedelic psychotherapy in the space.   In this episode: Eudaimonic vs hedonic well being The neurobiological and psychological overlaps between nature relatedness and the psychedelic experience How both psychedelics and nature relatedness promote mindfulness and experiences of awe Ideas for combining psychedelic therapy and experiences of nature to enhance health benefits   Quotes: “Nature connectedness is a mediator for some of the benefits to cognition and mood obtained from actually spending time in nature, having contact with nature.” [6:57] “There was a study published last year by a Finnish research group and one of the most common after effects of psychedelic mystical experiences they found was this sustained, positive shift in peoples' relationship to nature.” [17:35] “Psilocybin has this capacity to facilitate this fairly robust, rapid, but most importantly sustained increase in nature relatedness. And the really mysterious and interesting thing is that it can do this even when it's administered in a clinical setting.” [22:47] “The restorative effect of nature obviously benefits both the person having the therapy and the therapist, and it potentially allows for the outdoor nature-based setting to become part of the therapy itself.” [31:00] “If you're going to do any kind of psychedelic nature connection, nature immersion therapy, it's very important to have a cozy, secure structure that people have got as a safe place.” [35:31]   Links: Dr. Gandy on Twitter Dr. Gandy's 2020 article The Potential Synergistic Effects between Psychedelic Administration and Nature Contact for the Improvement of Mental Health Dr. Gandy's 2019 article From Egoism to Ecoism: Psychedelics Increase Nature Relatedness in a State-Mediated and Context-Dependent Manner Psychedelic Medicine Association Porangui

This episode of the Plant Medicine Podcast features a conversation about kratom with Dr. Oliver Grundmann. Dr. Grundmann earned his bachelors in pharmacy and European pharmacy license from University of Münster in 2004, after which he pursued graduate studies at the University of Florida, where he is now a clinical professor in the College of Pharmacy. His research interests focus on investigating the use of natural products as novel treatments for a variety of physical and mental conditions. Dr. Grundmann is a leading kratom researcher and has published numerous articles on the substance, examining the plant medicine and its use using a variety of methodologies.  In this episode, Dr. Grundmann introduces kratom (scientific name mitragyna speciosa) and discusses its pharmacology and potential as both a medicine and a drug of abuse. The kratom tree is native to southeast Asia and belongs to the same botanical family as the coffee plant. The leaves of the kratom tree contain a wide variety of active alkaloids and they are consumed orally to produce a psychoactive effect.  Dr. Grundmann explains that kratom is unique because the primary alkaloids mitragynine and 7-hydroxymitragynine are opioid agonists, yet the substance does not fit neatly into the opiate category as it lacks certain properties of the classic opioids such as morphine or heroin. For example, respiratory depression is not observed with the use of kratom, while this is a hallmark effect of opioids at high doses—and one of the major dangers associated with the use of these drugs.  Another way in which kratom is unique is that its effects are highly dose dependent. At lower doses, Dr. Grundmann explains, the plant tends to have a more energizing effect, while higher doses lead to a more sedating experience.  In this conversation, Dr. Grundmann also shares insights into kratom use in America based on survey research he has conducted. While scientific research into kratom remains a small field, this type of survey research helps to give insight into the potential kratom has as a plant medicine through data which shows the variety of conditions people are attempting to treat through kratom use.  As kratom consumption increased in the United States and the plant gained notoriety, its use became associated with the treatment of chronic pain and opioid withdrawal. Dr. Grundmann's research has been showing, however, that users are also turning to kratom for dealing with conditions such as depression, anxiety, and PTSD. These initial findings provide fertile soil for further research into kratom's potential medicinal applications.   In this episode: The pharmacology of mitragyna speciosa The legality of kratom in the United States The current state of scientific research into the effects of kratom consumption Contraindications for kratom use Potential uses for kratom to treat both mental and physical ailments Various methods for kratom consumption   Quotes: “Just because a substance binds to an opioid receptor doesn't mean that it shows all of the same properties as, for example, morphine, or oxycodone, or fentanyl, or heroin.” [14:20] “When we talk here one to five grams per dose, three times a day—the potential to develop a use disorder, kratom use disorder, basically, is relatively low. When we talk about really taking high amounts of an extract or also of the powder for example, let's say above eight grams, ten grams per dose, more frequently—four, five, eight times a day—then there is the potential to develop a dependence on it.” [18:52] “Between 70%–85%… [of] folks were in the range of one to five grams and didn't have to go above five grams to maintain alleviation of their symptoms for which they are using kratom… That indicates to me that there's no risk of tolerance up to five grams per dose.” [22:53] “Surprisingly, we had a large group now in the second survey who were using it to treat—self-treat—symptoms of ADHD or PTSD and nothing else aside from that. So it's really a very diverse population of users that we're seeing with kratom.” [25:09]   Links: Dr. Grundmann's Profile at the University of Florida  Dr. Grundmann on LinkedIn Psychedelic Medicine Association Porangui

This episode of the Plant Medicine Podcast welcomes Dr. Angela Carter (they/them) to discuss the intersection of the LGBTQIA2S+ community and psychedelics. Dr. Carter is a queer, transgender, and genderqueer naturopathic primary care physician who also works as a midwife, sexual assault examiner, and health equity advocate in Portland, Oregon. They also serve as both the vice-chair and the equity in training subcommittees co-chair of the Oregon Psilocybin Advisory Board. In addition to these positions, Dr. Carter serves as the chair of the Transgender Health Program Community Advisory Board at Oregon Health & Science University. They also volunteer with many organizations including the Fireside Project, Black Rock City Emergency Services, and Queerdome. Dr. Carter begins this conversation by sharing exciting new research currently being conducted which involves LGBTQIA2S+ individuals and psychedelic therapies. While this particular area of research remains small, it is growing and the fruits of these studies will be an important step for better understanding how these new therapies can serve gender and sexuality minorities, and help facilitators understand the unique concerns of people in the LGBTQIA2S+ community. Dr. Carter illustrates these types of concerns by discussing the prevalence of gender binaries within psychedelic spaces. They describe how in a clinical setting it is prevalent to have both a male and a female facilitator, but this leaves no room for gender-nonconforming people to guide experiences—something which could be preferable if the patient themselves shares this identity. Dr. Carter also discusses this gender binary in traditional contexts. It is common for ayahuasca ceremonies to provide separate spaces for men and women, again leaving no space for gender-nonconforming people. This reification of the gender binary and the often patriarchal organization of the ayahuasca ceremony can have serious impacts on the set and setting, especially for people in the LGBTQIA2S+ community. Dr. Carter emphasizes the importance of making space for folks in the community so that they are able to receive therapy, attend ceremonies, and participate in integration with others who share similar identities. This shared identity, they emphasize, ensures that LGBTQIA2S+ people don't feel out of place in contexts that ought to be healing. Dr. Carter closes by discussing how members of the LGBTQIA2S+ community experience disproportionate rates of mental illness, further illustrating the crucial importance of equity in accessing psychedelic medicine.    In this episode: Problems of representation and access for LGBTQIA2S+ individuals in the psychedelic space Current research being done on the intersection between psychedelic therapies and unique issues faced by gender and sexuality minorities Preparations to take before guiding a psychedelic experience for LGBTQIA2S+ people, particularly if you do not come from the community How plant medicines could have unique benefits for the LGBTQIA2S+ community Issues of poverty faced by marginalized peoples and how to support equity of access to emerging psychedelic therapies   Quotes: “For some people that idea of melding, of becoming one and losing all of those unique pieces of themselves, doesn't fit their paradigm of a spiritual connecting experience.” [10:47] “It's precious, that centering of our community—to be able to sit with people who just understand.” [19:42] “Psychedelics offer the opportunity for connection of the self to something greater, something outside, a bigger community, spirituality, and really do a huge amount to heal peoples' relationships with substances.” [25:20] “Marginalized communities have been really impacted, largely, by the war on drugs, which has put millions of people in jail for drug offenses and stolen their ability to make income, stolen their ability to connect with community and we really need to heal that.” [33:34]   Links: Fruiting Bodies Collective Chacruna Institute Queering Psychedelics 2019 Conference Queerdome on Facebook  Portland Psychedelic Society Psychedelic Medicine Association Porangui

This episode of the Plant Medicine Podcast features a discussion of psychedelics and meditative practices with Nate Macanian. Nate is a meditation teacher and psychedelic guide from New York with a background in cognitive neuroscience. He also creates mindfulness content for leading meditation apps such as Calm, Simple Habit, and Wellness Coach, as well as retreat centers such as Synthesis and Omega Institute.  Nate begins this discussion describing how he was initially exposed to meditation and psychedelics. This first exposure came while Nate was a student at the University of Michigan and his immediate passion for meditation led him to found a student organization to further explore meditative and contemplative practices with his peers. Nate also describes guiding friends through psychedelic experiences in his college arboretum, before he had ever even heard of the idea of trip sitting.  Turning to meditative practices themselves, Nate describes how psychedelics can be incorporated into one's meditation routine in a variety of ways and for a variety of different forms of meditation. What he stresses, however, is to examine the intention behind bringing plant medicines into the practice. But if they are incorporated mindfully, psychedelics can help bring meditative practices into sharper relief—microdoses help to amplify awareness and reveal the habits of the mind while larger doses work to connect one to layers of experience previously hidden to consciousness. While meditation and psychedelics share certain goals and can both be used for therapeutic ends, there are also differences between them. Nate describes psychedelics as an elevator which takes people directly to a destination, whereas meditation is more like a winding staircase as the practice requires continual effort and consistency to progress. Nate also distinguishes meditation and psychedelic experiences phenomenologically. He stresses that the goal of meditative practices is not to mimic the feeling of a trip. Instead, meditation works to focus the attention on the whole spectrum of human experience, some of which can be boring, tedious, or dull. Psychedelics, on the other hand, provide specific kinds of experiences which are intense and colorful, but these differences are what allow meditative practices and psychedelic journeys to have a symbiotic relationship.    In this episode: Nate's journey being introduced to mindfulness and psychedelics The importance of intention in meditation Incorporating plant medicines into one's meditative practices Psychedelics, meditation, and the default mode network in the brain Why set and setting is also important for meditation   Quotes: “If you include a larger dose in your meditation practice, you might find that there are layers that were previously unseen and latent, living under the surface, that start to come up and this is where a lot of shadow work happens.” [14:00] “When the default mode network is off, we have this increased susceptibility to our immediate environment and this is why it's so important to surround yourself with positive people and be in a nice, calm, safe place.” [22:24] “I think there's absolutely a place for psychedelics to be included in your meditation practice as long as it's intentional and as long as you feel like your success as a meditator is not attached to your use of any substance.” [26:59] “Meditation as a practice is not about really forcing ourselves to have some experience, but to train our awareness, to become a more whole person, a more fulfilled person, a more loving person.” [33:33]   Links: Nate's website Psychedelic Medicine Association Porangui

On this episode of the Plant Medicine Podcast, Mitchell Gomez of DanceSafe discusses how to reduce harm by chemically testing substances prior to consumption. Mitchell is a graduate of New College of Florida and holds a masters from University of Colorado Denver. He joined the DanceSafe team in 2014 and has been serving as the executive director since 2017. In addition to his work at DanceSafe, Mitchell also acts as a harm reduction consultant for MAPS. In this conversation, Mitchell shares the origin story of DanceSafe and describes the important work they do. He mentions that testing drugs is illegal in many states, but following a precedent set by needle exchanges, the justice system seems to turn a blind eye to DanceSafe’s activity. Transitioning to the present day, Mitchell discusses the current state of the drug market, sharing information on adulterants and false marketing for a variety of substances from ketamine and LSD to cocaine and MDMA. Prohibition is at the root of these issues, he claims, as this is what encourages things such as selling fentanyl while claiming it is another opioid, as fentanyl is more potent and thus easier to smuggle in smaller quantities. Another government-related issue Mitchell mentions is the data the state gathers on drug-induced medical incidents. This data groups a variety of substances together, making it difficult to determine the actual cause of the medical emergency. Turning to the importance of chemically testing drugs, Mitchell stresses the benefits of knowing what you are consuming. While a single test with the right reagent can tell a lot about a substance, Mitchell recommends using a wide variety of tests as many drugs are often adulterated even if they do contain the substance they were sold as. Knowing if a drug is cut with another substance and what this substance could be helps people make more informed decisions about what they put in their bodies. Especially in the era of the opioid epidemic, this kind of information can be legitimately lifesaving.     In this episode: The origin of DanceSafe and the services they provide How to use fentanyl test strips Common drugs currently being falsely marketed as MDMA New opioids which are laid on blotters like LSD Why using multiple reagents to test substances is a smart idea Chemically testing mushrooms vs learning mycology to identify species   Quotes: “One of the things we know is that the speed at which new drugs are entering the market is accelerating.” [15:08] “Fentanyl, for a non-opioid user, a milligram might be enough to kill you. One milligram. If you’re alone, if there’s nobody there to call 911, that might be enough to impact a non-opioid user’s breathing.” [18:44] “Nobody has ever been arrested for just having a test kit. That’s never happened. If they find a test kit as part of a larger drug investigation, they will include a paraphernalia charge for that test kit as a means of coercing plea deals.” [21:28] “These are problems caused by prohibition. We could have fair trade, organic cocaine in twenty-five days if we just ended the drug war.” [33:00]   Links: DanceSafe’s Website DanceSafe on Instagram Psychedelic Medicine Association Porangui

Dr. Lynn Marie Morski is the president of the Psychedelic Medicine Association, host of the Plant Medicine Podcast, the founder of Plant Medicine.org, and the medical director for Way of Leaf.com. She is a Mayo Clinic-trained physician in family medicine and sports medicine, as well as an attorney and former adjunct law professor.Topics discussed on this episode:Lynn Marie's mission is to educate clinicians about the healing potential of psychedelicsHer Plant Medicine Podcast was created with the intention of serving as an 'encyclopedia' of psychedelics and their therapeutic effectsThe Psychedelic Medicine Association was founded as a resource for clinicians, and shares the latest psychedelic research and offers panels on topics that are immediately applicable to clinical practiceThe story of Lynn Marie's personal journey with psychedelics and how it inspired her change of path from being a doctor at the VA where she felt profoundly misalignedLynn's advice if you're trying to change careers is to have a mission statement, and also a list of things that you are clear you do and don't enjoy professionallyYou need to be honest with yourself about the aspects of your professional life so far that have brought you energy as well as those that have drained youWe need to understand that the average doctor has little to no knowledge of psychedelics, and we should not blame them for this because they did not have this education in medical school and may simply lack exposure to new trends in psychedelic medicineThe future potential for careers in psychedelics is bright! There are so many ways to potentially work in the psychedelic space - we need a psychedelic skills career center!Lynn Marie feels that there needs to be a somatic component to psychedelic integrationIdeally integration professionals are trauma-informed - especially to help integrate cerebral insights with the nervous systemWe need integration professionals who know how to work with both psychedelic 'emergence' and psychedelic 'emergency'ResourcesWebsite: psychedelicmedicineassociation.orgTwitter: https://twitter.com/Psychedelic_MedFacebook: https://www.facebook.com/psychedelicmedicineassociationLinkedIn: https://www.linkedin.com/company/68258009/admin/IG: https://www.instagram.com/psychedelicmedicineassociation/ www.plantmedicine.orgTwitter: https://twitter.com/plantmedpodcastFacebook: https://www.facebook.com/plantmedicinepodcastLinkedIn: https://www.linkedin.com/in/lynn-marie-morski-md-esq/IG: https://www.instagram.com/plantmedicinedotorg

In this episode of the Plant Medicine Podcast, Adam Aronovich returns to discuss the phenomenon of psychedelic narcissism. Adam is a doctoral candidate at the Universitat Rovira i Virgili in Spain, focusing on Medical Anthropology and Cultural Psychiatry. He is an active member of the Medical Anthropology Research Center (MARC) and part of the Ayahuasca Community Committee at the Chacruna Institute for Psychedelic Plant Medicines. In the last four years he has conducted extensive fieldwork in the Peruvian Amazon, where he has been doing qualitative research in collaboration with ICEERS, the Beckley Foundation, and, more recently, the Centre for Psychedelic Studies at Imperial College. Beyond his work conducting and coordinating research, Adam regularly facilitates workshops at the Temple of the Way of Light, a prestigious healing center in the Iquitos area. In this wide-ranging conversation, Adam unpacks some of the darker sides of the modern psychedelic movement, discussing the psychosocial dynamics around psychedelic use which can lead to things such as ego inflation, conspiratorial thinking, and narcissism. Adam recalls his own experiences slipping into messianic fantasies during a period of initial enthusiasm around psychedelic experiences. He views issues of alienation and lack of social support as being instrumental in leading to these types of delusions following profound spiritual experiences. While it is difficult to reach people who’ve slipped into psychedelic narcissism, Adam suggests that communal support is the best safeguard against these dangers and the most effective strategy for grounding people who’ve lost touch with reality. Drawing on his academic expertise, Adam distinguishes traditional uses of plant medicines from the Western paradigm for approaching psychedelics. He stresses the relational and communal aspects of the spiritual traditions which use psychedelics ceremonially. The pro-social aspects of these wisdom traditions, he claims, help safeguard against the traps of psychedelic narcissism and ego inflation, as there are established mechanisms for keeping people grounded following intense spiritual experiences.  Adam closes the discussion with an insightful analysis of modern gurus and self-proclaimed shamans. Adam encourages people to beware of deeply held spiritual fantasies, where a master can appear as more than human. Instead, he emphasizes that even skillful and well-intentioned healers are themselves nothing more than human beings, so there will always be imperfection and messiness. This does not, however, mean that impactful work cannot happen—in fact, this insight helps protect against the idolization of charismatic psychedelic personalities, which can lead to harmful experiences.   In this episode: Defining psychedelic narcissism Clinical vs coloquial understandings of narcissism The intersections of the psychedelic movement and conspiracy theories The importance of social and communal support for avoiding ego inflation following psychedelic or spiritual experiences How psychedelic experiences can actually deepen ego attachments and accentuate narcissistic tendencies The importance of humor in combating spiritual narcissism   Quotes: “Many of the underlying ideologies upon which Western cultures were built, like hyper-individualism and so on, kind of predispose us and prime us for certain aspects of narcissism.” [5:36] “Ego inflation, spiritual narcissism, messianic episodes—all of these are things that are fairly common within both people who are in some sort of spiritual or psychedelic path.” [12:17] “In traditional societies for the most part really there isn’t such a thing as a self-proclaimed shaman. A person doesn’t wake up one morning and is like ‘oh, I’m the shaman’—that’s a title or a role or a recognition given to that person by the community.” [38:03] “The best measure of whether somebody is genuine and helpful is not whatever credentials or titles he assigns to himself, but rather what other people feel. So, you know, you will know a tree by its fruits.” [45:08] “Having these experiences by themselves does not necessarily mean spiritual growth or psychological development or any enhanced benefit if we’re not constantly, painfully, mindful of how we actually integrate and embody those things in daily life over very long periods of time.” [54:29]   Links: Adam on Instagram Temple of the Way of Light Psychedelic Medicine Association Porangui

This episode of the Plant Medicine Podcast is the final installment in a three-part series with Dr. Julie Holland. Dr. Holland is a psychiatrist specializing in psychopharmacology, and she is also the author of many books, including her most recent work Good Chemistry: The Science of Connection, from Soul to Psychedelics which discusses the neurochemistry behind human connection. She is also a medical monitor for several MAPS PTSD studies using MDMA-assisted psychotherapy and has worked for decades on US drug policy reform based on harm reduction principles. In addition to this work, Dr. Holland has nine years experience running a psychiatric emergency room as an attending physician on the faculty of NYU school of medicine and she continues her psychiatric work in her private practice in New York City.  In this episode, Dr. Holland speculates on the future of psychedelic therapy and the emerging issues within the broader psychedelic movement. Lamenting the lack of governing organizations and accountability, Dr. Holland discusses the complexities of regulating an industry with a history of operating underground and in legal grey areas. This raises questions such as how to grandfather-in established psychedelic practitioners now that various coursework in psychedelic therapy and systems for credentials are beginning to emerge.  Another issue related to legality which Dr. Holland discusses is the relation between the medical establishment and psychedelic therapies. The fact that individuals interested in pursuing plant medicines for therapeutic reasons are not able to easily consult with primary care doctors is a huge hurdle to harm reduction, and, as Dr. Holland points out, this leaves the responsibility for ensuring safety entirely on the psychedelic practitioners. Because these practitioners range from underground ayahuasca circles to clinically approved, legally operating therapists the amount of attention and care paid to harm reduction can vary greatly, which is why it will be essential to establish standards and best practices for psychedelic therapy as demand continues to increase. Dr. Holland also discusses the issues of “psychedelic capitalism” which are coming to the fore as these treatments become more mainstream and more accessible. While there are no clear answers for how to navigate the intersection of psychedelic therapies and capitalist market dynamics, this is an issue that deserves care and attention so that there can be equitable access to these medicines. Dr. Holland closes with a discussion of the parasympathetic nervous system–the “rest and digest” mode–and its importance for not only personal health, but also social well-being.    In this episode:   Why it is essential to begin establishing best practices and safeguards around emerging psychedelic therapies and other practices involving plant medicines Issues that arise from the intersection of capitalist market dynamics and the emerging psychedelic industry The future of medical consultations prior to consuming plant medicines Activating the parasympathetic nervous system and its pro-social impacts   Quotes:   “I think part of it is just this fear that if we admit there are some bad actors, that the whole house of cards is gonna fall.” [9:26] “Just because of the way capitalism is, there is IP, there is proprietary information, there is anti-competitive behavior. That to me also really needs to be addressed.” [11:31] “In any interaction there is a choice of being hurtful or helpful, and it’s a choice, everyday.” [20:18] “Anyone who can out themselves should, because it will move this whole thing along a lot more. If you are a soccer mom who also microdoses, put that bumper sticker on your car.” [24:58]   Links: Dr. Holland’s website Good Chemistry: The Science of Connection, from Soul to Psychedelics Psychedelic Medicine Association Porangui

L'ospite dell'ottava puntata di Illuminismo psichedelico è Jonas Di Gregorio, fondatore dello Psychedelic Literacy Fund, un fondo per la traduzione di libri psichedelici.Jonas vive a San Francisco ed è autore di Terapie psichedeliche, il solo altro podcast in lingua italiana dedicato alla psichedelia. In questa puntata Jonas ci parla dei tanti podcast psichedelici statunitensi (e non solo), un panorama ricchissimo che spazia da Psychedelics Today, a The New Health Club, passando per The Psychedelic Therapy, Plant Medicine Podcast, fino ad arrivare a The Third Wave Podcast. Un elenco ricchissimo a cui mi sono permesso di aggiungere The Duncan Trussel Family Hour, il podcast ideato dallo stand up comedian Duncan Trussell da cui è stata tratta la serie Netflix Midnight Gospel. E pensate che ce ne sono ancora moltissimi altri…

This is the trailer to Plant Medicine Podcasts to educate the importance of the spiritual, religious, and personal reasons why these catalysts have been utilized since beginning of humanity. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/dillyn-hoffman/message Support this podcast: https://anchor.fm/dillyn-hoffman/support

In Episode 2 of Season 2, I will be talking about Sacred Plant and Earth Medicine. I talk about my first sacred plant medicine experience, my relationships with plant medicine, and some healing benefits of them. Tune in to hear my experiences and get some information on plant allies that I've used along my healing journey. As I mentioned in the episode, these are medicines that should be handled in a sacred and safe manner. Please do your research and listen to your intuition if you're feeling called to try any medicine for the first time. Resources: Previous Episodes: “Melie's Healing Journey” “Healing With Others- My Healing Journey with Plant Medicine and Esoteric Knowledge by Jazmin M.” Plant Medicine Podcast with Dr. Lynn Marie Morski @plantmedicinedotorg https://thethirdwave.co @thirdwaveishere Thank you for listening, I appreciate you!!!

How will doctors who don't know about psychedelic therapies, learn to be receptive to these innovative compounds as valuable tools for their patients? Dr. Lynn Marie Morski, host of the Plant Medicine Podcast, has a brilliant idea–to form an association dedicated to educating medical practitioners about psychedelics. On today's episode, we discuss why Lynn Marie created the Psychedelic Medicine Association. We talk about what it means to create a coalition of ethically aligned actors and how to advance equal access to entheogenic compounds. Lynn Marie shares her entrepreneurial challenges and her dreams about where this association could go in the next 5 to 10 years. As you'll learn on the show, Lynn Marie has quite an impressive background. She is a physician, an attorney, a podcaster, and the author of Quitting by Design. She works with the Veterans Administration and hosts the Plant Medicine Podcast. LINKS Psychedelic Medicine Association Psychedelic Medicine Association Virtual Launch Event Plant Medicine Podcast Quitting by Design TIMESTAMPS :06 - How psychedelic medicine can change the way we believe we must achieve to be loved :14 - Lynn Marie's successful Plant Medicine Podcast :23 - Why Lynn Marie created an association to educate doctors on the value of psychedelics :29 - Creating coalitions of ethically aligned actors and equal access to psychedelic :40 - Where Lynn Marie sees the Psychedelic Medicine Association in 5-10 years :45 - Founding members, Lynn Marie's team, and how you can get involved. :53 - Lynn Marie speaks directly to psychedelic practitioners

Dr. Lynn Marie Morski is a Mayo Clinic-trained physician in family medicine and sports medicine, as well as an attorney and former adjunct law professor.  She hosts the Plant Medicine Podcast, is the founder of Plant Medicine.org, and serves as medical director for WayofLeaf.com. Dr. Morski worked at the Veterans Administration for nine years, and her biggest frustration during that time was that she was unable to discuss the benefits of many medications she knew could help the veterans she was serving, like cannabinoid treatments and psychedelic-assisted therapy. Dr. Morski practiced medicine for 14 years, and after leaving clinical medicine, she made it her mission to help fill the gap in the medical community's knowledge of psychedelics by educating her fellow physicians on the plant medicines and entheogens that could bring life-changing relief to their patients, while also educating potential users on what options they could seek for treatment of their conditions beyond the pharmaceuticals they're sold on commercials. In furtherance of this mission, she started the Plant Medicine Podcast to bring scientific researchers, practitioners, and those who have been personally affected by the healing powers of these plants together to help educate the public on what is possible and help further research and decriminalization of these substances. She also founded PlantMedicine.org to serve as a repository of information and resources for those seeking to learn more about these medicines. Find out more information about Dr. Lynn Marie Morski at https://www.plantmedicine.org/ ; the podcast at https://www.plantmedicine.org/podcast ; Instagram @plantmedicinedotorg ; https://quittingbydesign.com/ ; and the podcast at https://quittingbydesign.com/quit-happens-podcast/ --- Support this podcast: https://anchor.fm/wishwell/support

Dr. Lynn Marie is back with us on the show to share the latest updates on her life after quitting the VA and starting Plant Medicine Podcast and Plant Medicine.org to bring scientific researchers, practitioners, and those who have been personally affected by the healing powers of these plants together to help educate the public on what is possible and help further research and decriminalization of these substances.